Cargando…
Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data
BACKGROUND: To evaluate incidence of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with abatacept in clinical trials. METHODS: This pooled analysis of 16 randomized, double-blind/open-label trials, with ≥ 1 abatacept (intravenous or subcutaneous) arm, and with/wit...
Autores principales: | Simon, Teresa A., Dong, Lixian, Winthrop, Kevin L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798209/ https://www.ncbi.nlm.nih.gov/pubmed/33430948 http://dx.doi.org/10.1186/s13075-020-02399-2 |
Ejemplares similares
-
Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008) -
Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006) -
Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011) -
Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials
por: Simon, Teresa A., et al.
Publicado: (2019) -
Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)